The need for new “pull” incentives to stimulate antibiotic R&D is widely recognized. Due to the global diversity of health systems, combined with different challenges faced by antibiotics used in different types of healthcare settings, there is no one-size-fits-all solution. Instead, different “pull” incentives should be tailored to local contexts, priorities, and antibiotic types. Policymakers and industry should collaborate to identify appropriate solutions at the local, regional, and global levels.
Get full access to this article
View all access options for this article.
References
1.
M. J.Renwick, D. M.Brogan, and E.Mossialos, “A Systematic Review and Critical Assessment of Incentive Strategies for Discovery and Development of Novel Antibiotics,”Journal of Antibiotics69 (2016): 73-88j.
The Review on Antimicrobial Resistance: Chaired by JimO'Neil, Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, May2016; World Bank, Drug-Resistant Infections: A Threat to Our Economic Future (Discussion Draft), 2016, Washington, D.C.
L. L.Silver, “Challenges of Antibacterial Discovery,”Clinical Microbiology Reviews24, no. 1 (2011): 71-109.
6.
J. H.Rex, M.Goldberger, B. I.Eisenstein, and C.Harney, “The Evolution of the Regulatory Framework for Antibacterial Agents, ”Annals of the New York Academy of Science1323 (2014): 11-21.
7.
See supra note 3 for reference to The Review on AMR.
M. O. A.Sommer, C.Munck, R.V.Toft-Kehler, D. I.Andersson, “Prediction of Antibiotic Resistance: Time for a New Preclinical Paradigm?”Nature Reviews Microbiology15 (2017): 689-696.
10.
M. S.Kinch, “ An Overview of FDA-Approved Biologics Medicines, ”Drug Discovery Today20, no. 4 (2015): 393-398.
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Policy Position: Sustainable Models to Overcome the Challenging Economics of Antimicrobial R&D, available at <http://partnerships.ifpma.org/uploads/documents/218_1485276320.pdf> (last visited March 22, 2018).
17.
J.Goldhammer, K.Mitchel, A.Parker, B.Anderson, and J.Sahil, “The Craft of Incentive Prize Design: Lessons from the Public Sector,”2014, available at <https://www.issuelab.org/resource/the-craft-of-incentive-prize-design-lessons-from-the-public-sector.html> (March22, 2018); see Rendwick et al., supra note 1; J. H. Rex and K. Outterson, “Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach,” The Lancet Infectious Diseases 16, no. 4 (2016): 500-505.
18.
Id. (Rex and Outterson); G.Daniel, M.Schneider, and M.McClellan, “Addressing Antimicrobial Resistance and Stew-ardship: The Priority Antimicrobial Value and Entry (PAVE) Award,”JAMA318, no. 12 (2017): 1103-1104.
19.
See supra notes 13 (The Review on AMR reference), 15 (Chorzelski et al.), and 16 (IFPMA policy position).
20.
P.Viale, M.Giannella, R.Lewis, E. M.Trecarichi, N.Petrosillo, M.Tumbarello, “Predictors of Mortality in Multidrug-Resistant Klebsiella Pneumoniae Bloodstream Infections,”BioMed Central Infectious Disease14 (2014): 572; A. F. Shorr, M. D. Zilberberg, S. T. Micek, and M. H. Kollef, “Predictors of Hospital Mortality among Septic ICU Patients with Acinetobacter spp.bacteremia: A Cohort Study,” Expert Review of Anti-Infective Therapy 11, no. 10 (2013): 1053-1063; T. P. Lodise, N. Patel, A. Kwa, J. Graves, J. P. Furuno, E. Graf-funder, B. Lomaestro, and J. C. McGregor, “Predictors of 30-Day Mortality among Patients with Pseudomonas Aeruginosa Bloodstream Infections: Impact of Delayed Appropriate Antibiotic Selection,” Antimicrobial Agents Chemotherapy 51, no. 10 (2007): 3510-3515.
21.
A. S.Kesselheim and K.Outterson, “Fighting Antibiotic Resistance: Marrying New Financial Incentives to Meeting Public Health Goals,”Health Affairs29, no. 9 (2010): 1689-1696; A. Sertkaya, J. T. Eyraud, A. Birkenbach, et al., “Analytical Framework for Examining the Value of Antibacterial Products,” available at <https://aspe.hhs.gov/report/analytical-framework-examining-value-antibacterial-products> (last visited March 22, 2018).
